In this episode, host Henry Norton sits down with Bruno Dheedene, CEO and Founder of Rods&Cones, a surgical streaming platform that’s solving one of the most overlooked problems in the OR – nobody can actually see what the surgeon is doing. Bruno shares how he bootstrapped the company from a 2018 incubation project to a… Continue reading Nobody Can See What’s Happening in Surgery with Bruno Dheedene
Podcast Categories: Crux of MedTech
The flagship show. The conversations founders, executives, and investors in MedTech want to hear.
Why Medtech Is Still Decades Behind Fintech with Esther Reynal
In this episode, your host Henry Norton is joined by Esther Reynal de St Michel Richardot, Founding Partner at THENA Capital, to discuss why so many medtech founders are building technologies without understanding their real market challenges and how early-stage thinking about value propositions and stakeholder needs can make or break a healthcare startup. Esther… Continue reading Why Medtech Is Still Decades Behind Fintech with Esther Reynal
Venture is first and foremost an Adventure with Iwan van Vijfeijken
In this episode, host Henry Norton sits down with Iwan van Vijfeijken, CEO of Microsure and a four-time medtech entrepreneur who’s been through the full cycle of startup life. Iwan made the jump from NXP Semiconductors to medtech 15 years ago, starting as employee number one at Dermasun Medical. Since then, he’s navigated three more… Continue reading Venture is first and foremost an Adventure with Iwan van Vijfeijken
Building Acquisition-Ready Medtech from Series A with Gautam Kainth
In this episode, host Henry Norton sits down with Gautam Kainth, Partner at TCP Health Ventures, to unpack why medtech investing fundamentally differs from traditional tech and what founders need to know about positioning their companies for strategic exits. Gautam brings over 20 years of investment experience with $1+ billion in deployed capital across 30+… Continue reading Building Acquisition-Ready Medtech from Series A with Gautam Kainth
100% of Nothing is Nothing with Raymond Cohen
Raymond Cohen has spent 40+ years in medtech, never at a big company but always building. After taking Axonics from whiteboard to $500M in revenue and a Boston Scientific exit, he’s now chairman of multiple high-growth ventures. In this episode, he breaks down what actually makes a company acquirable, why founders need to get over… Continue reading 100% of Nothing is Nothing with Raymond Cohen
30 Da Vinci Copycats Will Fail with John Murphy
John Murphy left a corporate COO role to become employee number one at Virtual Incision then spent the next 14 years building MIRA, the world’s first miniaturised soft tissue surgical robot. The pitch? A little robot on the inside, instead of a big one reaching in from the outside. The journey included five alpha iterations,… Continue reading 30 Da Vinci Copycats Will Fail with John Murphy
10x Isn’t Enough to Change Medicine with Alan Cohen
Alan Cohen has built companies, sold companies, started a price war between tech giants and now invests in what he calls “tech med” at DCVC, a $4.5bn deep-tech fund. The distinction matters: tech med starts with data and computational methods, not hardware. In this conversation, Alan unpacks the investments that excite him, from real-time surgical… Continue reading 10x Isn’t Enough to Change Medicine with Alan Cohen
Vivasure Exits to Haemonetics for €185 Million, an Interview with Andrew Glass
In this episode of The Crux of MedTech, host Henry Norton sits down with Andrew Glass, CEO of Vivasure Medical, fresh off announcing the company’s acquisition by Haemonetics Corporation. Andrew shares the full journey, from his early days in drug-eluting stents at Guidant (later Abbott), to running a $10M sales territory, to making equity investments… Continue reading Vivasure Exits to Haemonetics for €185 Million, an Interview with Andrew Glass
The Glucose Sensor That Predicts the Future with Mark Tapsak
In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom’s earliest employees. Mark Tapsak left Medtronic for a “crazy startup” called Dexcom after seeing data so compelling he couldn’t say no. Two decades later, he’s back in the CGM game as Chief Science Officer at Glucotrack,… Continue reading The Glucose Sensor That Predicts the Future with Mark Tapsak
Cooling the Pancreas to Save Lives with Robert Kieval
In this episode, Henry Norton sits down with Robert Kieval, CEO of Arctx Medical Inc, to talk about a condition that sends 300,000 Americans to the ER every year with no approved treatment options waiting for them. Robert shares how Arctx is developing a deceptively simple solution: a cooling catheter that targets pancreatic inflammation from… Continue reading Cooling the Pancreas to Save Lives with Robert Kieval